No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Madrigal Pharmaceuticals Analyst Ratings
Madrigal Pharmaceuticals' Rezdiffra Shows Strong Market Growth and Positive Outlook, Justifying Buy Rating
JMP Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $427
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Sell Rating, Announces Target Price $155
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?